12,372 trials
Schizophrenia · Schizoaffective Disorders
Primary: Change From Baseline to Endpoint in Weight — 2.76; 2.40; 0.65 kilograms — p=0.065
HIV Infections
Primary: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 — 77.3; 42.9 Percentage of Participants
Neuralgia, Postherpetic
Primary: Summary of Adverse Events — 124; 14; 5; 17 subjects
Gastrointestinal Stromal Tumor
Primary: Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase — 27.3; 6.4 weeks — p=<0.001
HIV Infections
Primary: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 — 77.7; 41.0 Percentage of Participants
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants Reporting Solicited Local or Systemic Reactions Post-Dose 5 of DAPTACEL® Vaccination — 75; 70; 36; 24 Percentage of Participants
Iron Deficiency Anemia
Primary: Hemoglobin — 1.49; 0.89; 1.02 ng/mL
Diabetes
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy — 9.41; 9.53; 9.61; 6.93 percent
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — 8.25; 8.35; 8.19; 7.59 percent
Diabetes
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — 8.36; 8.48; 8.44; 7.83 percent
Diabetes
Primary: Change From Baseline in Hemoglobin A1 (A1C) at Week 24 — 8.04; 7.93; 8.02; 7.79 percent
Diabetes Mellitus, Type 1
Primary: Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint — 8.88; 8.68; -0.69; -0.59 percent of HbA1c — p=0.332
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Change From Baseline in HbA1c at Week 12 — -0.70; -0.30 Percent — p=<0.001
HIV Infection · Infection, Human Immunodeficiency Virus
Primary: Percentage of Participants Not Meeting the Definition of Virologic Failure at or Prior to Week 24 — 92.1; 94.2 Percentage of participants
Rotavirus
Primary: Serum Anti-Rotavirus IgA Response — 89; 7 Participants — p=0.003